Viking Therapeutics stockholders approve 2024 equity plans and re-elect directors at annual meeting

Viking Therapeutics, Inc.

Stockholders re-elected Brian Lian (50.5M for, 17.4M withheld) and Lawson Macartney (22.3M for, 45.7M withheld) as Class III directors.
2024 Equity Incentive Plan approved (48.5M for, 19.3M against).
2024 Employee Stock Purchase Plan approved (67.1M for, 0.7M against).
Advisory say-on-pay approved (63.2M for, 4.5M against).
Ratification of Marcum LLP as auditor for FY2024 approved (87.4M for, 0.7M against).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.